Orion Stock – Fundamental Analysis Solide
Orion: KGV 28.88 · Dividend yield 1.75 % · FScore Solide · As of 11/11/2026
Orion: KGV 28,9 · Dividendenrendite 1,8 % · FScore 65 (Solide) · Stand: 11.11.2026
Fundamental Data & Ratios (Balance sheet update: 2/17/2026)
| Balance Sheet | Total Assets | 2.01 bn | Equity Ratio | 63.91 % |
| Balance Sheet | Total Equity | 1.28 bn | ROA | 24.89 % |
| Cashflow | Capital Expenditures | -97.60 m | P/FCF | 65.98 |
| Cashflow | Free Cash Flow | 219.20 m | – | – |
| Cashflow | Operating Cash Flow | 316.80 m | P/CF | 45.65 |
| Income | Earnings per Share (diluted) | 3.56 | Div. Yield | 1.75 % |
| Income | Net Income | 500.30 m | P/E | 28.88 |
| Income | Shares Outstanding | 140.69 m | P/B | 11.26 |
| Income | Total Revenue | 1.89 bn | P/S | 7.65 |
Ratios calculated on: 11/11/2026
Industry
Similar Companies
| Company | P/E | Dividend Yield | FScore |
|---|---|---|---|
| Chugai Pharmaceuticals Co., Ltd. | 27.10 | 3.81 % | Solide |
| Takeda Pharmaceutical Co Ltd | 97.62 | 2.83 % | Solide |
| Otsuka Holdings Co., Ltd. | 18.91 | 1.00 % | Solide |
| Daiichi Sankyo Co Ltd | 17.76 | 2.23 % | Schwach |
| Astellas Pharma Inc | 92.93 | 2.72 % | Solide |
| Shionogi & Co., Ltd. | 15.25 | 1.87 % | Solide |
| Eisai Co., Ltd. | 30.66 | 3.21 % | Solide |
| Kyowa Hakko Kirin Co., Ltd. | 19.53 | 2.48 % | Solide |
| Eli Lilly and Company | 62.55 | 0.42 % | Solide |
| Novo-Nordisk A/S | 11.85 | 4.27 % | Solide |
Ratio History (10 Years)
| Year | P/E | Dividend Yield | Equity Ratio |
|---|---|---|---|
| 2016 | 20.04 | 4.38 % | 56.80 % |
| 2017 | 12.58 | 5.85 % | 60.32 % |
| 2018 | 14.39 | 6.73 % | 64.40 % |
| 2019 | 13.78 | 4.57 % | 67.42 % |
| 2020 | 21.68 | 4.87 % | 75.25 % |
| 2021 | 19.93 | 4.86 % | 65.55 % |
| 2022 | 33.71 | 3.30 % | 67.14 % |
| 2023 | 14.55 | 4.17 % | 60.40 % |
| 2024 | 26.68 | 3.89 % | 61.87 % |
| 2025 | 26.84 | 2.58 % | 61.69 % |
| 2026 | 28.88 | 1.75 % | 63.91 % |
Company Description
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler for the treatment of asthma and chronic obstructive pulmonary disease.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.orion.fi
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more